At NewLink Genetics, we are discovering, developing, and working to commercialize novel immuno-oncology therapies to fundamentally change the way cancer is treated. Through strategic alliances with others who share our vision, we have the opportunity to maximize our contributions to science and the patients who need us most.
We are also working with Merck & Co. to develop rVSV-ZEBOV,† a vaccine to target Ebola. As part of the agreement, NewLink Genetics received an up-front payment of $30 million from Merck. In February 2015, NewLink Genetics received a $20 million milestone payment after initiating a key clinical trial in Africa. NewLink Genetics and Merck also contracted with the Biomedical Advanced Research and Development Authority (BARDA) for an initial payment of $30 million, and in October 2015, received another $18 million to support further scale-up of manufacturing. In September 2015, NewLink Genetics also received $8.1 million, with future options up to $5.2 million, from the Defense Threat Reduction Agency (DTRA) to continue further research. The vaccine rVSV-ZEBOV was originally developed by the Public Health Agency of Canada (PHAC) and licensed by a wholly owned subsidiary of NewLink Genetics.
Partner with us
By partnering with other companies, we have many more opportunities to make a difference in the lives of patients with cancer. Our doors are open to new partnerships in immuno-oncology, where we’re investing in our collective future. For new partnership inquiries, please contact us.
†Licensed by Merck & Co.